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Abstract: The optical coherence tomography angiography (OCTA) is a noninvasive imaging technology which aims at imaging blood vessels in retina by studying decorrelation signals between
multiple sequential OCT B-scans captured in the same cross section. Obtaining various vascular
plexuses including deep and superficial choriocapillaris, is possible, which helps in understanding
the ischemic processes that affect different retina layers. OCTA is a safe imaging modality that does
not use dye. OCTA is also fast as it can capture high-resolution images in just seconds. Additionally,
it is used in the assessment of structure and blood flow. OCTA provides anatomic details in addition to the vascular flow data. These details are important in understanding the tissue perfusion,
specifically, in the absence of apparent morphological change. Using these anatomical details along
with perfusion data, OCTA could be used in predicting several ophthalmic diseases. In this paper,
we review the OCTA techniques and their ability to detect and diagnose several retinal vascular
and optical nerve diseases, such as diabetic retinopathy (DR), anterior ischemic optic neuropathy
(AION), age-related macular degeneration (AMD), glaucoma, retinal artery occlusion and retinal
vein occlusion. Then, we discuss the main features and disadvantages of using OCTA as a retinal
imaging method.
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Optical coherence tomography angiography (OCTA) is a novel imaging modality that
noninvasively and rapidly images the retinal microvasculature in multiple layers with
a resolution resembling histologic appearance [1,2]. It can identify retinal vessels by the
detection of intensity and/or phase property variations of optical coherence tomography
(OCT) signals in multiple B-scans at the same point resulting from red blood cell movement [3]. OCTA generates angiographic images by employing motion contrast imaging
to obtain high-resolution volumetric blood flow information with excellent intra-visit
repeatability [4].
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OCTA employs an algorithm called the split spectrum amplitude decorrelation angiography (SSADA), which detects the flow of blood in the retinal microvasculature with
no use of dye [5]. SSADA allows for obtaining OCTAs of high quality using the same
available speeds in a retinal commercial OCT system [6]. An advantage of using SSADA
is that it enhances the flow detection’s signal-to-noise ratio [7]. Normal OCT provides
in-depth imaging of the retinal and choroidal vasculature. The retina consists of a threeneuron circuit that detects light and then transmits that signal to the brain via the optic
nerve. The photoreceptors are located in the outer retina, which is avascular. Thus, OCTA
images of the outer retina show no vessels under normal conditions. The outer retina
receives its oxygen from the choriocapillaris, the richly vascular layer of the eye as deep
as the retinal pigment epithelium (RPE), which is a monolayer of cells that divides the
outer retina from the choroid. OCTA readily images both the choroid and choriocapillaris.
After detecting light, photoreceptor cells transmit their electrical signal to bipolar cells in
the middle retina, which in turn connect to retinal ganglion cells in the inner retina. These
funnel into the optic nerve, which travels posteriorly through the optic chiasm to the brain.
Oxygen to the middle and inner retina is supplied by the deep and superficial plexuses of
the retinal vasculature, both of which are beautifully imaged by OCTA. Finally, there is
a peripapillary vasculature supplied by the central retinal artery that encircles the optic
nerve and supplies the pre-laminar optic nerve. Thus, under normal conditions, OCTA
provides high-resolution imaging of vessels in the choroid, choriocapillaris, middle and
inner retina, and peripapillary vessels.
Thanks to OCTA, retinal, choroidal and optic nerve vasculature can be studied safely
with no dye injection. Specific layers of the retina and choroid can be seperately visualized
by en-face OCTA which helps in detecting vascular changes level in the choriocapillaris,
the middle choroid, the inner retina, and the outer retina [6]. It can demonstrate vessel
density (VD), shape of the foveal avascular zone (FAZ), and alteration in retinal blood
flow [8]. OCTA acquisition time is short compared to indocyanine green angiography
(ICGA) or fluorescein angiography (FA) because there is no dependence on the dye’s
flooding kinetics. Instead, acquisition time depends on parameters such as scan volume,
speed of eye tracking system, scan speed, resolution, and numbers of scans averaged [9].
OCTA’s ability to detect the shape and morphology of FAZ is very helpful as FAZ is
an indicator of the perifoveal microcirculation [10]. Important retinovascular diseases, such
as retinal vein occlusion (RVO) and Diabetic Retinopathy (DR), interfere with the retinal
microvascular circulation and alter FAZ size and shape [11]. OCTA can detect capillary
dropout in DR better than FA because of lack of leakage [12].
In the following sections, we will discuss the advantages of OCTA as a new imaging modality in comparison with other modalities such as FA and ICGA. We will also
provide a short review of clinical findings of OCTA in several retinal and optic-nerverelated diseases. The review aims to guide researchers regarding the capabilities of OCTA
over current technologies in diagnosing ophthalmic diseases, which gives it a significant
translational value.
OCTA Versus FA and ICGA
FA and ICGA are important diagnostic imaging techniques for evaluating multiple
retinal diseases, in particular ones of vascular or inflammatory origin. These invasive
tests use intravenous dye followed by multiple photographs over at least (10 to 30) min.
They provide 2-D images with dynamic visualization of blood flow and a wide field of
view [13,14]. Their images can be interpreted depending on the dye leakage, pooling,
and staining patterns. While color fundus photography, FA, and ICG are generally presented as 2D images, there historically have been modalities for generating some degree
of depth to these images. Scanning laser ophthalmoscopy (SLO) is an imaging modality
based on a form of confocal microscopy [15]. It suffered in the past from an inability to
represent true color, but improvements in this regard have been made. More recently, SLO
has been combined with adaptive optics imaging techniques [16]. Despite some notable ad-
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vantages to SLO, the technology is not ubiquitous in most ophthalmology clinics, and most
commercial FA and ICG machines present 2D images.
Several studies in the literature have investigated using FA imaging modality diagnosing the posterior segment of the eye [17]. Despite that, FA has some limitations such as its
inability to visualize different levels of major capillary networks separately. This is because
FA is unable to differentiate deep capillary plexus (DCP) from superficial capillary plexus
(SCP). Additionally, it is hard to use FA in obtaining enhanced images of perifoveal capillaries because it has a challenge in focusing images in case of macular edema existence [18].
Moreover, FA is an invasive, time-consuming and relatively expensive modality, which
makes it not ideal for regular use in clinical settings. Fluorescein dye is known to be safe;
however, its side effects include nausea, allergic reactions and anaphylaxis in some rare
cases [6].
OCTA is a technique that is used to acquire angiographic information non-invasively
without the need to use dye [17]. OCTA can capture images rapidly and check if the
acquired images are of sufficient quality. If the acquired images are of low quality, OCTA
can repeat the capturing process until images of good quality are obtained. FA in contrast
has a time frame that is limited to capturing the capillary net images that are optimal.
Individual vascular plexuses with the segmentation of the choriocapillaris, the middle
choroid, the inner retina, and the outer retina can be visualized in the acquired en-face
images [6]. OCTA outperforms FA in detection of macular ischemia because there is no
dye leakage [19]. While FA cannot visualize DCP, OCTA is able to accurately delineate
microvascular changes and ischemia in both DCP and SCP [1]. This is because OCTA does
not have dye leakage and tissue staining problems, in addition to the longer wavelengths
used in OCTA that can better penetrate through intraretinal hemorrhage [20]. Furthermore,
OCTA is able to detect neovascularization elsewhere (NVE) while providing better visibility
of new vessels than that produced by FA [21]. However, while NVE in the posterior pole
can be readily imaged with OCTA, it suffers from the drawback that it does not image the
periphery where a significant amount of NVE occurs.
2. Retinal Vascular Diseases
2.1. Diabetic Retinopathy (DR)
In 2015, there were about 415 million people diagnosed with diabetes mellitus worldwide [22]. Microvascular complications are the most common causes of diapetic patients’
morbidity and mortality [23]. DR is an early clinical sign of microvascular complications
in diabetes mellitus [24]. In developed countries, DR is considered a primary blindness
cause among working-age adults [25].
DR has earlier signs which include tortuosity progression, caliber changes in arterioles
and venules, and alterations in FAZ shape and size [26]. In addition, it is recognized by
blood–retinal barrier breakdown, microaneurysm formation and apericyte loss. Another
significant early event of DR is capillary nonperfusion which leads to tissue damage and
ischemia over time [27]. OCTA offers the advantage of quantification of early features of
DR particularly changes of vessel density in the macula and changes in FAZ area [28].
FA has been used to study foveal microvasculature and was able to show capillary
dropout areas in DR; however, detection of the capillary alterations was limited by the
capillary networks and the leakage superposition [29]. The OCTA provides a 3-D noninvasive vascular mapping of macular perfusion [30] while separating DCP and SCP;
meanwhile, FA can barely show the DCP [6]. OCTA have shown that microvascular
changes in DR are not confined to the SCP [31]. On the contrary, parafoveal-capillary
dropout occur initially at the level of the DCP [32]. There are many obvious alternations,
which can be detected in the OCTA scans due to the developing of DR. In the following
subsection, these changes are discussed in detail.
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2.1.1. Detection of DR
FAZ Enlargement
Size and morphology of the FAZ is an important indicator of capillary perfusion
status within the macula; it correlates with the grade of DR, and abnormalities of FAZ can
sometimes indicate macular ischemia [33].
One of the various clinical applications of OCTA in DR is its ability to evaluate the shape
and the size of the FAZ area. Several clinical studies (Takase et al. [34], Suzuki et al. [35],
Dupas et al. [36], Freiberg et al. [37], Eladawi et al. [38], Sahndu et al. [39]) reported
enlargement of FAZ in diabetic patients versus normal healthy controls. Figure 1 shows
enlargement of FAZ in DCP and SCP in a diabetic patient versus a normal control.
Takase et al. [34] found an enlargement of FAZ in the SCP in the healthy controls
compared to eyes of patients of diabetic with DR and enlargement of FAZ in the DCP in the
healthy controls compared to the eyes of diabetic patients with DR. Salz et al. [20] found
an enlargement of FAZ in the SCP in the healthy controls compared to the eyes of diabetic
patients with DR.
Suzuki et al. [35] also found an enlargement of FAZ in the SCP in the healthy controls
compared to the eyes of diabetic patients with DR and enlargement of FAZ in the DCP in
healthy controls compared to the eyes of diabetic patients with DR. They concluded that
the enlargement of the FAZ is statistically significant in the DCP at a rate of 5.1% per year.
There was also enlargement of FAZ in the SCP, but it was not statistically significant.

Figure 1. FAZ enlargement. (a) SCP for a normal subject, (b) DCP for a normal subject, (c) SCP for a
diabetic patient, and (d) DCP for a diabetic patient.
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Dupas et al. [36] found significant enlargement of FAZ in the SCP in the healthy
controls compared to the eyes of diabetic patients with DR and normal visual acuity (VA).
They found further enlargement of FAZ in the diabetic patients with DR and reduced VA.
They concluded that the enlargement of FAZ in diabetic patients with DR is negatively
correlated with VA.
Freiberg et al. [37] found enlargement of the mean horizontal FAZ diameter in patients
with DR versus normal healthy controls, as well as absence of normal orientation of the
angle of the maximum FAZ diameter in DR patients due to the irregular configuration of
the FAZ. Balaratnasingam et al. [40] recorded a significant correlation between enlargement
of FAZ and poor visual prognosis in patients with DR. They also found that this positive
correlation is modulated by patient’s age, such that an increase in patient’s age is associated
with poorer vision. Table 1 lists the average areas of the FAZ in both normal and DR cases.
Table 1. Average areas of FAZ in both normal and DR cases.

Study

No. of
Patients

Age

SCP-FAZ
(Control) (mm2 )

SCP-FAZ
(DR) (mm2 )

DCP-FAZ
(Control) (mm2 )

DCP-FAZ
(DR) (mm2 )

Takase et al. [34]
Salz et al. [20]
Suzuki et al. [35]
Dupas et al. [36]

20
11
13
22

65.8 ± 8.7
55.7 ± 10
66.5 ± 10.4
30 ± 6

0.25 ± 0.06
0.3 ± 0.11
0.31 ± 0.09
0.20 ± 0.07

0.38 ± 0.11
0.49 ± 0.19
0.36 ± 0.13
0.3 ± 0.11

0.38 ± 0.11

0.56 ± 0.12

0.45 ± 0.17

0.71 ± 0.2

FAZ Morphology
Large individual variations can be detected by the evaluation of the FAZ area in both
healthy [41,42] and diabetic [43] eyes. Using OCTA, FAZ morphological parameters (a
metric called acirculatory index and axis ratio) were evaluated by Krawitz et al. [44] in
patients with diabetes versus healthy controls. In OCTA, acircularity index (irregularity of
FAZ) and axis ratio (the ratio of the maximum and minimum axes of a best-fit ellipse fitted
to the FAZ) were found helpful in distinguishing between control subjects and diabetic
subjects with no DR, NPDR, and proliferative diabetic retinopathy (PDR). Higher axis
ratio and acircularity index are considered statistical significant indicators of retinopathy
advanced stage. A strong negative correlation was found between FAZ acircularity index
and BCVA. The change in the FAZ acircularity index in DR patients is probably because of
the capillary dropout.
While quantification of FAZ area and shape has become increasingly common in
the literature when characterizing sequelae of various retinal vascular diseases, there is
another school of thought on the matter that calls into question the value of these metrics.
One source of concern is that FAZ areas vary within the normal population. The value of
various metrics to gauge the shape of the FAZ has also been called into question, as the
clinical utility of varying distortions of “normal” shape have unclear clinical implications
at the moment.
Vessel Density at the Macula
While macular vessel density is decreased in diabetics [45], there are conflicting data
as to whether it is more reduced in the SCP than the DCP, vice versa or to approximately
the same extent [46]. OCTA studies revealed a reduction of macular VD in diabetic patients
with DR with positive correlation to the severity of DR [45]. Figure 2 shows reduction of
VD in both DCP and SCP in a diabetic patient compared to control.
Zahid et al. [47] showed significantly lower VD in subjects of diabetes with DR when
compared to healthy control eyes in both SCP and DCP. Dupas et al. [36] found that VD
was reduced significantly in the SCP and DCP in diabetic subjects with DR with normal VA
in comparison with healthy controls. This reduction is even more in patients of diabetes
with DR and decreased VA (without macular edema). They concluded that the reduction
in vessel density in patients with diabetes with DR is positively correlated with decreased
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VA. Shen et al. [48] reported a significant reduction in the density of the vessels in the SCP
in patients with diabetes with early DR when compared to healthy controls. However, no
significant difference was found in retinal thickness between diabetic subjects and healthy
controls. They concluded that compromised microvascular circulation precedes retinal
structural changes. Table 2 lists the average VD in both normal and DR cases.

Figure 2. Vessels density. (a) SCP of normal control, (b) DCP of normal control, (c) SCP of the a
diabetic patient, and (d) DCP of a diabetic patient.
Table 2. The average VD in both normal and DR cases.

Study

No. of
Patients

Age

SCP-VD
(Control) (mm2 )

SCP-VD
(DR) (mm2 )

DCP-VD
(Control) (mm2 )

DCP-VD
(DR) (mm2 )

Zahid et al. [47]
Dupas et al. [36]
Shen et al. [48]

13
22
49

56.66 ± 12.65
30 ± 6
56.4 ± 10.1

55.6 ± 1.7
49.1 ± 2.5
54.1 ± 2.1

48.2 ± 4.6
44.1 ± 2.5
47.82 ± 4.62

60.6 ± 1.5
50.6 ± 3.3

53.6 ± 3.2
44.3 ± 3.2

Microaneurysms
Microaneurysms were identified on OCTA as a well-demarcated saccular or fusiform
shapes of focally dilated capillaries in the SCP and DCP but mainly in the deep plexus [49].
Matsunaga et al. [50] compared the detection of microaneurysms in diabetic retinopathy
using FA and OCTA. They found that only 23% of microaneurysms detected on FA were
identified on OCTA. They also found variation in both shape and size of microaneurysms
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detected by the two techniques. Microaneurysms appeared on FA as uniform round dots,
while they appeared on OCTA smaller in size with multiple different shapes such as
fusiform, solid round or round with dark centers.
Couturier et al. [12] compared the detection of microaneurysm in diabetic retinopathy
using FA and OCTA. They found that 62% of microaneurysms detected on FA were
identified on OCTA. They found that the number of microaneurysms detected per eye
was 11.7 ± 7.1 on FA versus to 7.3 ± 3.9 on OCTA. Moreover, microaneurysms detected by
OCTA were mainly in the DCP (4.4 ± 2.1 per eye) versus (2.9 ± 2.3 per eye) in the SCP.
Salz et al. [19] also compared the detection of microaneurysm in diabetic retinopathy
using FA and OCTA. They found that 75% of microaneurysms detected with FA were
identified on OCTA. They found that the number of microaneurysms detected per eye was
10.0 ± 6.9 on FA versus to 6.4 ± 4.0 on OCTA. Another study by Miwa et al. [51] found that
OCTA can detect only 41.0 ± 16.1% of microaneurysms seen on FA images in eyes with
DR. The detection of microaneurysm in OCTA and FA has some difference that may be
explained by the nature of microaneurysms themselves, as some of them are not completely
patent so red blood cells (detected by OCTA) may not pass into the microaneurysm but the
smaller fluorescein molecules (detected by FA) still can pass into the microaneurysm [50].
It may also be explained by the fact that blood flow within some microaneurysm was too
slow (less than 0.3 mm per second) to be detected by OCTA [12]. A third explanation is
that some of the hyperfluorescent dots seen on FA (supposed to be microaneurysms) are
actually curved or coiled capillaries as seen on OCTA [51]. This is a notable weakness of
OCTA relative to traditional FA.
Cotton-Wool Spots
Cotton-wool spots detected as swelling of the nerve fiber layer on OCT have been
shown to have impaired capillary perfusion on OCTA [50].
Intraretinal Microaneurysmal Abnormalities (IRMA)
OCTA shows IRMA as a group of looping vessels adjacent to areas of impaired
capillary perfusion with their caliber greater than of surrounding capillaries [50].
Preretinal Neovascularization
PDR could be characterized by the preretinal neovascularization (neo-vascularization
of the disc (NVD)) or neovascularization of the retina elsewhere (NVE)), which are abnormal, pathological vessels that protrude through the internal limiting membrane into the
vitreous cavity caused by up-regulation of vascular endothelial growth factor (VEGF) and
other angiogenic factors [52]. OCTA showed NVD as a group of disorganized vessels protruding from the disc into the vitreous [50]. Akiyama et al. [53] found that NVD arises from
outside the physiological cupping into the vitreous cavity on OCTA. De Carlo et al. [54]
found that preretinal neovascularization appears on OCTA as a fan of vessels extending
into the vitreous bordering or overlying areas of retinal capillary dropout. The presence of
NVD on OCTA is an indication for initiating treatment with anti-VEGF and/or panretinal
photocoagulation. Multiple areas of NVE would also qualify as indications, although small
areas of NVE that remain stable can often be safely observed.
Diabetic Macular Edema (DME)
Diabetic macular edema (DME) pathogenesis is linked to the blood barrier breakdown
in retina with fluid leakage from microaneurysms. In diabetic eyes, VEGF is believed to
be a main cause of hyperpermeability of retinal vasculature. Hence, anti-VEGF agents
are usually considered the main and effective therapy for DME, which improves macular
edema and visual prognosis in subjects with DME [55]. An OCTA study conducted by
Haritoglou et al. [56] has found out that the high rate of the formation of macular microaneurysm (Mas) in diabetic patients is a predictor of the development of significant macular
edema. Another OCTA study conducted by Hasegawa et al. [57] to analyze the relationship
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between DME and microaneurysms distribution in different retinal layers concluded that
there is a correlation between microaneurysms existing in the DCP and DME pathogenesis.
Mane et al. [58] studied the relation between the retinal capillary dropout areas
in DME and the location of cystoid spaces. The authors found out that cystoid spaces
theco-localized with areas of the capillary dropout, particularly in the DCP. There is no
reperfusion that occurs after the DME resolution. OCTA has limitations in imaging of DME
due to its inability to detect leakage. Hence, it cannot differentiate leaking from non-leaking
microaneurysms. Another limitation is that there are defects of OCTA segmentation in the
edematous macula. Decisions regarding treatment for DME are still primarily based on
the presence of central cystoid spaces on structural OCT in combination with decreased
visual acuity. OCTA does not typically play a role in this setting. However, severe capillary dropout in the macula that persists even with resolution of DME is something the
treating clinician should consider. Macular ischemia can limit vision, and patients with
center-involving DME whose vision fails to improve with resolution of edema often have
significant macular ischemia that has damaged photoreceptors and reduced visual potential. In these cases, the clinican may consider withholding further treatment due to its
futility. A further discussion of capillary dropout in the macula and abnormalities of the
foveal avascular zone follows below.
2.1.2. Detection of Progression of DR FAZ Area
OCTA studies prove progressive enlargement of FAZ in a positive correlation with
the severity of DR. Salz et al. [20] reportedd a positive correlation between enlargement of
FAZ and increasing severity of DR. They reported that FAZ area was 0.30 ± 0.11 mm2 in
normal healthy controls, then enlarged to 0.41 ± 0.19 mm2 in patients of diabetes without
DR, then enlarged to 0.49 ± 0.19 mm2 in patients of diabetes with nonproliferative diabetic
retinopathy (NPDR) and then enlarged to 0.76 ± 0.16 mm2 in diabetic patients with PDR.
This conforms with the findings of Bhanushali et al. [59], who found out that FAZ area
was 0.38 ± 0.01 mm2 in normal healthy controls, then enlarged to 0.45 ± 0.03 mm2 in
diabetic patients with mild NPDR, then enlarged to 0.46 ± 0.01 mm2 in diabetic patients
with moderate NPDR, then enlarged to 0.46 ± 0.02 mm2 in diabetic patients with severe
NPDR and then enlarged to 0.47 ± 0.02 mm2 in diabetic patients with PDR.
Vessel Density at the Macula
OCTA studies prove a progressive reduction of VD in both DCP and SCP with
increasing severity of DR. Bhanushali et al. [59] found reduction of VD in SCP from
49.7 ± 0.55 mm2 in normal healthy controls to 40.1 ± 0.58 mm2 in diabetic patients with
mild NPDR, then reduced to 39.2 ± 1.21 mm2 in diabetic patients with moderate NPDR,
then reduced to 38.5 ± 0.76 mm2 in diabetic patients with severe NPDR and then reduced
to 38.9 ± 1.38 mm2 in diabetic patients with PDR. They also reported a reduction of VD
in DCP from 53.1 ± 0.73 mm2 in normal healthy controls to 40.2 ± 0.53 mm2 in diabetic
patients with mild NPDR, then reduced to 39.7 ± 1.57 mm2 in diabetic patients with moderate NPDR, then reduced to 39.4 ± 0.68 mm2 in diabetic patients with severe NPDR and
then reduced to 39.2 ± 0.94 mm2 in diabetic patients with PDR.
Kim et al. [60] found that vessel density is reduced progressively in both DCP and
SCP with severity increase of DR. They reported that the density of vessels in SCP was
0.42 ± 0.01 mm2 in normal healthy controls then reduced to 0.38 ± 0.03 mm2 in diabetic
patients with mild NPDR, then reduced to 0.34 ± 0.05 mm2 in diabetic patients with severe
NPDR and then reduced to 0.33 ± 0.04 mm2 in diabetic patients with PDR. They also found
that vessel density in DCP was 0.43 ± 0.01 mm2 in normal healthy controls, then reduced
to 0.42 ± 0.01 mm2 in diabetic patients with mild NPDR, then reduced to 0.40 ± 0.05 mm2
in diabetic patients with severe NPDR and then reduced to 0.39 ± 0.03 mm2 in diabetic
patients with PDR. Figure 3 shows a progressive reduction of vessel density with the
advancement of the stage of DR.
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Figure 3. DR progression. A progressive reduction of vessel density with the advancement of the
stage of DR.

2.1.3. Early Detection of DR
Microvascular damage occurs prior to the observation of retinopathy in clinical examination or fundus photography [61]. The initial diagnosis of NPDR usually detects
DR at a relatively advanced stage of microscopic vascular changes, which were not clinically or angiographically detectable as proven by histological studies of cadaver eyes in
humans [62].
The early detection of DR is effective in avoiding severe loss of vision in diabetic
patients [63]. Early microvascular changes in diabetic retina in patients with no DR has been
studied using OCTA. OCTA, being a non-invasive imaging modality, may be considered a
very helpful tool for clinical screening of eyes of patients of diabetes with DR [64].
FAZ Area
Several studies (de Carlo et al. [65], Takase et al. [34], Suzuki et al. [35], Dimitrova
et al. [66], Vujosevic et al. [67]) have demonstrated enlargement of FAZ area in diabetic
patients regardless of DR existence. De Carlo et al. [65] reported enlargement of FAZ in
healthy controls compared to the eyes of diabetic patients without DR.
Takase et al. [34] revealed enlargement of FAZ in the SCP in healthy controls compared
to the eyes of diabetic patients without DR and enlargement of FAZ in the DCP in healthy
controls compared to the eyes of diabetic patients without DR.
Suzuki et al. [35] revealed enlargement of FAZ in the SCP in healthy controls compared
to the eyes of patients of diabetes without DR and enlargement of FAZ in the DCP in healthy
controls compared to the eyes of diabetic patients without DR.
Dimitrova et al. [66] revealed enlargement of FAZ in the SCP in healthy controls
compared to the eyes of diabetic patients without DR. Vujosevic et al. [67] revealed enlargement of FAZ in the SCP in healthy controls compared to the eyes of patients of diabetes
without DR and enlargement of FAZ in the DCP in healthy controls compared to the eyes
of diabetic patients without DR. Other studies (Carnevali et al. [46], Simonett et al. [31],
Scarinci et al. [68], Cao et al. [64]) reported no statistical significance of the difference in
FAZ area in the SCP between diabetic subjects without DR and normal healthy controls.
Table 3 lists the average areas of the FAZ in both normal and early DR cases.
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Table 3. Average areas of FAZ in normal and early DR cases.

Study

No. of
Patients

Age

SCP-FAZ
(Control) (mm2 )

SCP-FAZ
(DR) (mm2 )

de Carlo et al. [65]
Takase et al. [34]
Salz et al. [20]
Suzuki et al. [35]
Dimitrova et al. [66]
Vujosevic et al. [67]

39
24
11
14
23
60

60 ± 20.55
62.9 ± 9.8
55.7 ± 10
66.5 ± 10.4
69 ± 9.01
57.4 ± 15.4

0.28 ± 0.13
0.25 ± 0.06
0.3 ± 0.11
0.31 ± 0.09
0.31 ± 0.10
0.28 ± 0.13

0.34 ± 0.10
0.37 ± 0.07
0.41 ± 0.19
0.36 ± 0.13
0.37 ± 0.11
0.35 ± 0.12

DCP-FAZ
(Control) (mm2 )

DCP-FAZ
(DR) (mm2 )

0.38 ± 0.11

0.54 ± 0.13

0.45 ± 0.17

0.70 ± 0.2

0.36 ± 0.14

0.49 ± 0.15

Vessel Density at the Macula
One of the early characteristics of microvascular alteration in the retina of patients
of diabetes is a reduction of VD. This reduction may be due to the alteration of retinal
neurovascular autoregulation, which regulates blood flow in response to metabolic demands [69].
Some studies (Carnevali et al. [46], Simonett et al. [31], Scarinci et al. [68]) reported
a statistical significance of the reduction of VD in DCP but not in SCP in diabetic eyes
without DR when compared to healthy control eyes. Several studies (Dimitrova et al. [66],
Cao et al. [64], Zeng et al. [70]) found a statistically significant reduction of VD in both
DCP and SCP in diabetic subjects without DR as compared to normal healthy subjects.
Furthermore, they reported no significant correlation between average VD and duration of
diabetes or HBA1c level.
Rosen et al. [71] found that perfused capillary density (PCD) is elevated in diabetic
subjects with no DR as compared to healthy subjects, and they suggested that PCD can be
used as a preclinical biomarker of diabetic microvascular disease. The different findings
between these studies may be related to the specific segmentation method employed.
Rosen et al. [71] selectively isolated capillaries from non-capillary blood vessels, and their
results revealed increased perfused capillary density. They suggested that this was an
autoregulatory response to increased metabolic demand. Other authors [31,46] have not
done that, which may explain their results of decreased vessel density in DCP.
Chen et al. [72] investigated fractal dimensions using OCTA in type 2 diabetic patients
without DR to characterize the macular microvascular network. They reported diminished
fractal dimensions in DCP in diabetic patients without DR as compared to healthy controls.
Table 4 lists the average VD in both normal and early DR cases.
Table 4. The average VD in both normal and early DR cases.

Study

No. of
Patients

Age

Carnevali et al. [46]
Simonett et al. [31]
Scarinci et al. [68]
Dimitrova et al. [66]
Cao et al. [64]
Zeng et al. [70]

25
28
20
29
71
66

22 ± 2
42.3 ± 8.6
38.5 ± 12.4
69 ± 9.01
57.4 ± 13.5
58.77 ± 12.3

SCP-VD
(Control) (mm2 )

SCP-VD
(DR) (mm2 )

DCP-VD
(Control) (mm2 )

DCP-VD
(DR) (mm2 )

51.5 ± 4.2
51.39 ± 13.05
55.72 ± 2.43
50.42 ± 3.73

58.7 ± 3.6
44.35 ± 13.31
51.34 ± 4.09
48.12 ± 4.01

41.53 ± 14.08
62.10 ± 2.11
52.71 ± 6.56

31.03 ± 16.33
57.66 ± 5.73
48.62 ± 6.39

2.2. Age-Related Macular Degeneration (AMD)
AMD is a primary cause of blindness of adults above 50 years old in developed
countries [73]. Neovascular AMD represents nearly 10% of AMD cases [74]. The onset of
neovascular AMD determines the progress of the development of AMD from intermediate
non-exudative to late exudative. Neovascular AMD refers to the abnormal growth of new
vessels either underneath the RPE (neovascularization type 1), between the retina and the
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RPE (neovascularization type 2), or starting within the retina (neovascularization type 3).
Types 1 and 2 neovascularization are known as choroidal neovascularization (CNV) as they
are derived from the choroidal circulation [75]. However, type 3 neovascularization refers
to the retinal angiomatous proliferation as it arises initially from retinal circulation [76].
CNV onset in AMD was determined by macular exudation onset, which is recognized
by either the leakage during FA [77], the existence of macular fluid in OCT [78], or the
existence of vascular flow abnormal pattern in OCTA [79]. The most popular category of
exudative AMD is type 1 CNV [76].
OCTA is also used in imaging the neovascular membrane inside the macula noninvasively. Even if there is no exudation, in OCTA, CNV type 1 is shown as vessels network
located between the Bruch’s membrane and the retinal pigment epithelium (RPE) [80],
whereas CNV type 2 is visualized as vessels network in the normally avascular outer
retina [81]. Furthermore, type 3 neovascularization is visualized as a discrete high flow
linear structure that extends from middle layers in the retina into the deep retina and
occasionally also past the RPE [82]. In Figure 4, an OCTA of an AMD patient showing
abnormal vessels in the choriocapillaris layer and the choroid is shown.
The sign of activity of CNV on FA is the leakage existence. OCTA is unable to evaluate
the existence of leakage or exudation, but it can potentially differentiate active from inactive
CNV by changes in the pattern of the vasculature. Active CNV appears on OCTA as a
branching and well-defined anastomosing tangle of vessels surrounded by dark halo
corresponding to blood, exudation or sub-retinal fibrosis. Inactive CNV appears on OCTA
as large mature vessels without anastomosis [83]. These distinctions are still not entirely
clear cut, and further study is ongoing.
OCTA is considered to be better than FA in identifying neovascular membranes due to
the absence of vascular obscuration by leakage from new vessels, which is typically seen on
FA [84]. OCTA could detect CNV type 1 in 67–100% of cases in comparison with FA [85]. SSOCTA (wavelength 1050 nm) is better than SD-OCTA (wavelength 840 nm) in visualization
of CNV because of the better penetration of the former into the choroid [86]. Cases of
dense subretinal hemorrhage secondary to CNV present a distinct challenge for OCTA,
as well as often FA. These hemorrhages block penetration of light, and thus the underlying
neovascular membranes and choriocapillaris cannot be imaged in these circumstances.
Type 1 CNV appears on the en-face OCTA as a well-defined entanglement of blood
vessels while it appears on cross-sectional OCTA as intrinsic flow in sub-RPE space [87],
while type 2 CNV appears on cross-sectional OCTA as hyper-reflective material with the
intrinsic flow in the sub-retinal space with thicker main vessel branch that is connected to
the choroid. The neovascular membrane is surrounded by a dark halo corresponding to
blood, exudation or sub-retinal fibrosis [88]. Mixed CNV type 1 and type 2 lesions appear
on cross-sectional OCTA as abnormal intrinsic flow above and below the RPE. Mixed CNV
type 1 and type 2 lesions can be visualized on en-face OCTA by varying the segmentation
depth, so the component of each type can be visualized on different slabs [89]. Type 3
neovascularization appears on the en-face OCTA as a tangle of blood vessels originating
from the DCP in the outer retinal slab while, it appears on the cross-sectional OCTA as a
hyper-reflective vascular structure with intrinsic flow extending from the outer retina slab
into the inner retina slab [88].
Farecki et al. [90] differentiated types of CNV using OCTA. Authors found that
CNV type 1 appears larger and less demarcated with predominant visibility on the choriocapillaris slab while CNV type 2 appears smaller and better demarcated with more
visibility towards the outer retina slab. Quantifying the neovascular networks extent in
CNV is very important for its well-known prognostic value [91]. The study conducted
by Costanzo et al. [92] has held a comparison between the CNV type 1 size that is produced using OCTA and ICGA. Results showed that OCTA and ICGA are comparable,
as they could provide information on CNV type 1 both quantitatively and qualitatively
with good reproducibility and inter-user agreement. This conforms with the results of
Amoroso et al. [93] and Lindner et al. [9].
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Figure 4. AMD. OCTA scan showing different plexuses for an AMD subject: (a) choroid layer,
(b) whole retina, (c) Choriocapillaris layer, and (d) avascular layer.

A potential risk exists for CNV developing in eyes of individuals who have unilateral CNV. This risk varied from 6% to 42% in different studies (Palejwala et al. [79],
Yanagi et al. [94], Roisman et al. [95], Amoroso et al. [93], Lindner et al. [7], De Oliveira
Dias et al. [96] Treister et al. [97]). In these studies, authors explained the various factors
that affect the subclinical CNV prevalence such as the duration and severity of AMD.
The subclinical CNV in fellow eyes in the first year has its prevalence more than doubled
as reported in the second-year follow-up [98].
Kuehlewein et al. [82] studied the response of CNV membranes to anti-VEGF using
OCTA. They showed that after treatment, the size and the density of vessels of the neovascular membrane were significantly reduced. These results conform with the findings
of Pilotto et al. [99], who revealed a reduction in the size of neovascular membrane 48 h
after treatment. However, there was no change found in the main central trunk of feeder
vessels. According to Bellou et al. [100], the main central trunk of feeder vessel might
resist anti-VEGF therapy because of the protection provided by the pericytes overlying
its endothelial cells, while the branching vascular network lacks the protective pericytes.
However, they are more responsive to anti-VEGF therapy.
OCTA can directly and non-invasively visualize the neovascular membrane in the
form of the thick central feeder vessel with vessels radiating from the lesion’s center in all
directions [86]. It can also monitor changes in this membrane, which precede the onset of
exudation. It may be in the form of increase in flow in the feeder vessels or increase in the
area of the neovascular membrane [7,101]. This can be very helpful in the management
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of neovascular AMD, which is an indication for treatment with intravitreal anti-VEGF to
suppress exudation. OCTA imaging can modify the current strategies (“treat and observe”
or “treat and extend”) for neovascular AMD treatment [102].
Spaide [103] studied the appearance of the CNV vasculature, which is treated with
injections of recurrent intravitreal anti-VEGF in eyes of 17 neovascular AMD subjects
using OCTA. The finding stated that diameter of the vessel in the neovascular membrane
remained larger than the normal vessels even after the treatment, which antagonizes the
normalization hypothesis of blood vessels in the eyes that are treated using repeated
intravitreal anti-VEGF.
The change in the size of the neovascular membrane in CNV patients in response to intravitreal anti-VEGF has been studied with OCTA. Cocas et al. [89] found a reduction of the
size of the neovascular membrane over a fellow up period of 4 weeks. Kuehlewein et al. [82]
found no change of the size of the neovascular membrane over a 3-months follow up period. Xu et al. [104] found enlargement of the neovascular membrane in 80% of cases
over a 12-month follow-up period, with doubling of the size of the membrane in 27% of
patients. OCTA is particularly effective at detecting quiescent CNV or subclinical CNV.
This is characterized by the presence of vessels with flow within drusenoid PEDs. In these
cases, structural OCT will detect the drusenoid PEDs but no fluid or other OCT features
suggestive of CNV. In the absence of exudation and clinical decreases in vision, these cases
can be safely observed, but closer monitoring of these patients is indicated. These vessels
could begin to exude fluid at almost any time, and the typical 6 month follow up schedule
that is typical of dry AMD patients would not be appropriate in these cases. In patients
with exudative AMD with active exudation, management decisions are primarily still
based on structural OCT findings. CNV-complicating chorioretinal inflammatory lesions
and central serous chorioretinopathy forms another set of conditions that is somewhat
beyond the scope of this survey. OCTA is an excellent imaging modality in these cases,
perhaps even the best, as it can distinguish between inflammatory lesions with and without
vessels and identify CNV in areas of CSR pathology, when other imaging modalities are
often unhelpful because these lesions cause leakage and OCTA abnormalities with or
without CNV.
2.3. Retinal Vein Occlusion
Retinal vein occlusion (RVO) is ranked the second most common vascular disorder
in retina after DR with significant visual impairment. Hypertension, open-angle glaucoma,smoking, thrombophilic disorders and diabetes are among the basic risk factors of
RVO [105]. Macular ischemia or macular edema is the leading cause of central vision
loss [106] in addition to its neovascular complications, including neovascular glaucoma
and vitreous hemorrhage [107]. Figure 5 presents the capillary non-perfusion in DCP and
SCP of RVO patient.
Almost all clinical and fluorescein angiographic findings that characterize retinal vein
occlusions and its later sequelae are demonstrated by OCTA. The principal characteristics
include collateral vessels formation, FAZ enlargement, decrease in capillary perfusion
and venous dilation [108,109]. OCTA is actually superior in detecting irregularities of the
FAZ and changes in DCP [110]. FA’s one advantage is that it shows physiologic leakage
and has a wider field of view of the peripheral retina [1,111]. In general, visual acuity in
BRVO correlates with macular edema, and vision improves as edema is reduced [112,113].
Reduction of ME alone, however, is not sufficient to produce good vision. The recovery of
VA may be limited after ME resolution because of foveal photoreceptor damage secondary
to macular ischemia, as concluded by OCT research [113,114]. Microvascular abnormalities, such as FAZ enlargement, microaneurysms, and capillary telangiectasia, in patients
with RVO are seen more so in the DCP than in SCP [115–118]. The vessels’ architectural
organization in the two plexuses could explain these findings. Transverse venules connect
the SCP large venules directly to the DCP. The DCP in turn drains into the large superficial
veins. Hence, in RVO patients, the intravascular pressure increase in large veins results in
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hydrostatic pressure elevation with retinal perfusion reduction in DCP. A direct connection
exists between the SCP and arterioles with high perfusion pressure and oxygenation in
the retina. This probably helps to protect against the ischemic insult incurred by increased
venous pressure in RVO [119].
Many studies (Wang et al. [120], Suzuki et al. [121], Kimura et al. [122], Cardoso
et al. [123]) compared microvascular changes in the eye affected with RVO versus the
fellow unaffected eye versus controls. They found reduction of the density of vessels in
the DCP and SCP, reduction of choriocapillaris density, thickened subfoveal choroidal
thickness, increased central macular thickness, and enlargement of the FAZ in eyes affected
with RVO versus fellow unaffected eyes. They also found a reduction of the density of
vessels in the DCP and SCP in the fellow unaffected eyes versus healthy controls.
OCTA images of RVO eyes have been analyzed by Spaide et al. [124], who concluded
that the formation of cystoid spaces occurs at areas of disturbed vascular flow in the SCP.
However, these cystoid spaces are absent or only present in areas of severely disturbed
vascular flow in the DCP. No observed alterations in the pattern of the DCP or SCP occurred
after resolution of cystoid spaces with treatment. Coscas et al. [117] concluded that in the
SCP, cystoid spaces are more common in eyes with central retinal vein occlusion (CRVO),
whereas in the DCP, they are more common in eyes with BRVO.
Several groups (Salles et al. [125], Balaratnasingam et al. [40], Samara et al. [126]) have
reported enlargement of FAZ in eyes with CRVO. Salles et al. [125] reported enlargement
of the mean FAZ area in the SCP from 0.25 in controls to 0.76 in patients with CRVO and
enlargement of the mean FAZ area in the DCP from 0.49 in healthy controls to 1.12 in
patients with CRVO. Samara et al. [126] reported enlargement of the mean FAZ area in the
SCP from 0.28 in the fellow eye to 0.31 in the BRVO eye and enlargement of the mean FAZ
area in the DCP from 0.41 in the fellow eye to 0.51 in the eye affected with BRVO.
Clinical studies (Salles et al. [125], Balaratnasingam et al. [40], Samara et al. [126],
Wakabayashi et al. [115]) reported that the enlargement of FAZ is significantly correlated
with poor visual prognosis in RVO patients. Balaratnasingam et al. [40] reported that
this negative correlation is modulated by patient age such that an increase in patient age
correlates with poorer vision. Salles et al. [125] reported that poor visual prognosis is
directly proportional to the size of FAZ in the SCP but not in the DCP.
Several clinical studies (Winegarner et al. [127], Wakabayashi et al. [115], Ghashut
et al. [128]) have studied the relationship between retinal perfusion and visual prognosis in
eyes with RVO after ME resolution using anti-VEGF therapy. They reported a significant
positive correlation between pre-treatment retinal perfusion and visual acuity at last follow
up. Thus, OCTA is able to provide visual prognostic information for patients with RVO.
Using OCTA, Shiihara et al. [129] studied the relationship between morphological
parameters (axial ratio and acircularity index) of the FAZ and BCVA in eyes with BRVO.
Results demonstrated that acirculatory index is not significantly correlated to BCVA in
RVO. However, axial ratio (also called axis ratio) is significantly correlated to BCVA. Their
finding suggests that the FAZ’s morphological characteristics are more valuable visual
prognostic indicators than the FAZ size alone in RVO eyes.
Collateral vessels in the retina tend to arise after BRVO more frequently than they
happen after CRVO. Collaterals are enlarged, existing capillaries that bypass venous
obstruction that is driven by hemodynamic and hydrostatic forces. Usually, these vessels
develop within weeks of RVO [130]. Collateral vessels course through DCP but not in the
SCP, which supports the serial arrangement of the DCP and SCP, with venous drainage
predominantly coursing through the DCP [131]. Freund et al. [132] used OCTA to study
the location of the collateral vessels that are associated with BRVO. They are curvilinear,
dilated channels that connect veins across the horizontal raphe or veins on opposite sides
of an occluded venous segment inside the same hemisphere of the retina. This conforms
with the findings of Arrigo et al. [133] that the collateral vessels are located in the DCP,
representing retinochoroidal anastomosis starting from the superficial retinal capillaries
and reaching the choriocapillaris and choroidal vessels to bypass the site of occlusion.

Appl. Sci. 2021, 11, 4158

15 of 28

Figure 5. RVO. OCTA scan showing various plexuses for RVO subject: (a) superficial plexus, (b) deep
plexus, (c) whole retina.

With BRVO eyes, Suzuki et al. [134] used OCTA to analyze collateral vessels and
how they are associated with visual outcomes and ME. They found that collaterals were
observed more frequently in eyes with major BRVO or ischemic BRVOS. Furthermore,
one-third of the collaterals were found to leak fluid, and MAs were found inside all
leaky collaterals. In eyes with collaterals, ME resolves quicker than in eyes that do not
have collaterals; however, no significant difference was found. While average baseline
central retinal thickness (CRT) is significantly higher in eyes with collaterals, the presence
of collateral vessels appears to have no effect on visual outcomes. One of the major
complications of ischemic RVO is neovascularization of the retina, which takes the form
of neovascularization of the disc (NVD) or neovascularization elsewhere (NVE). Retinal
ischemia can even drive the formation of NV in the anterior segment of the eye, causing
neovascular glaucoma (NVG), a particularly aggressive form of glaucoma [135]. NV is
highly abnormal, and these vessels can bleed spontaneously, causing vitreous hemorrhage
and sudden vision loss, or they can scar, causing tractional retinal detachment. An OCTA
study by Sogawa et al. [21] has analyzed NVE growth in an eye with hemi-CRVO. They
found that OCTA can clearly visualize NVE growth and its detailed microvasculature.
Identifying NV on OCTA is an indication for initiating or continuing anti-VEGF treatment
or beginning panretinal photocoagulation. Development of collateral vessels is not an
indication for anti-VEGF treatment.
Many of the manifestations of RVO have been attributed to increased levels of intraocular vascular endothelial growth factor (VEGF) [135]. VEGF drives both angiogenesis,
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resulting in NV formation, and incompetence of normal capillaries, causing macular
edema. Intravitreal anti-VEGF agents have become the mainstay of ME treatment, but this
edema usually recurs at the same location of cystoid spaces after reduction of intraocular
level of these agents [136]. Clinical studies (Spaide et al. [136], Falavarjani et al. [137],
Winegarner et al. [138]) have reported no significant improvement in retinal perfusion
or FAZ area in eyes with RVO after treatment with intravitreal anti-VEGF therapy and
resolution of ME.
2.4. Retinal Artery Occlusion (RAO)
During the RAO acute phase, the capillary flow collapse results in intracellular edema,
axoplasmic stasis, and retinal inner layers ischemic necrosis [6]. Usually, edema resolution
is accompanied by the recanalization and reperfusion of the the obstructed retinal artery
over the course of several weeks, but the infarction of the inner retina results in profound
vision loss. Ultimately, the retina is left atrophic and with persistent vessel narrowing [29].
The retinal arterioles, which are arranged in two layers that are morphologically
distinct, have a vital role in autoregulating blood flow in the retina. The superficial retinal
capillary plexus exists at the nerve fiber layer close to the disk (radial parapapillary capillaries); however, it is present predominantly inside the ganglion cell layer in the central
macular region. The DCP consists of intermediate and deep plexuses existing at inner
and outer planes of the inner nuclear layer, respectively. Perpendicularly oriented vessels
connect these capillary layers, which could be affected disproportionately by the ischemic
vascular disease. Capillary plexus ischemia in RAO might occur in one or more inner layers
of the retina resulting in ischemic edema, axoplasmic stasis and even death of the cells in
the nonperfused region. These vascular layers could be affected differently by the severity
of intracellular edema (there is capillary leakage or edema on OCT in RAOs), and the depth
and area of capillary nonperfusion of the retina. In addition, the visual prognosis could be
affected by the breadth of retinal capillary ischemia [139].
Branch retinal artery occlusion (BRAO) usually develops during the sixth or seventh
decade of life as unilateral, painless vision loss in the visual field corresponding to the
territory of the obstructed artery [140]. Montage OCTA is a technique that unites OCTA
images of adjacent retinal regions to provide a wide field of view while preserving the
microvascular details [6]. de Castro-Abeger used montage OCTA to evaluate a case with
BRAO. Montage of OCTA comprise OCT angiograms segmented between Bruch’s membrane and the inner limiting membrane (ILM). This uncovered severe decreased flow
distal to the obstruction and a very distinct border of capillary non-perfusion. Capillary
non-perfusion in the retina could be easily discerned in OCTA more than in FA due to the
OCTA absence of choroidal flush [141].
Bonini Filho et al. [142] studied the retina’s microvasculature in nonarteritic RAO
eyes using OCTA and FA. They found that OCTA imaging observed a vascular perfusion
decrease in deep and superficial retinal capillary plexus, which corresponded to the delayed
perfusion areas in FA imaging. They also revealed that it is sensitive for the characterization
of the extent of macular ischemia and for monitoring changes in the vascular flow within
the course of the disease.
Cases with central retinal artery occlusion (CRAO) are at a higher risk of ocular
neovascularization, so there is a recommendation for the retinal vasculature follow-up [143].
This is one of the important values of OCTA in follow up of cases with CRAO.
3. Optical Nerve Diseases
3.1. Glaucoma
Glaucoma is a main cause of irreversible blindness worldwide [144]. Glaucoma is a
multifactorial optic neuropathy of unknown etiology [145]. Elevated intraocular pressure
(IOP) is one of the risk factors for developing glaucoma, but it is not a sine qua non of
the disease, as many patients diagnosed with glaucoma are found to have normal IOP
levels at the time of diagnosis. One theory regarding the pathogenesis of glaucoma is that
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it is vascular in origin [146]. Studying ocular microcirculation in glaucoma is challenging
because of the difficulty in observing the microvasculature directly inside the retina’s
discrete layers and the optic nerve head (ONH) [147]. Fortunately, OCTA could potentially
help in understanding the microvascular circulation role in the ONH and retina [6,148].
The OCTA is able to provide a 3-D visualization of the vasculature of the ONH from the
disc surface to the lamina cribrosa, so it can be used as a diagnosis and evaluation of
glaucoma or glaucoma suspects [149].
Yarmohammadi et al. [150] have presented a study to compare OCTA performance versus spectral-domain (SD)-OCT’s in differentiating between glaucoma suspects, glaucoma
patients, and healthy subjects. The results showed that both ONH density of vessels (OCTA)
and the RNFL thickness (SD-OCT) have comparable diagnostic accuracy in differentiating
between glaucomatous eyes and healthy eyes.
Evaluation of optic disc perfusion by OCTA allows calculation of the optic disc flow
index, which has high sensitivity and specificity in diagnosing glaucomatous versus normal
eyes. The value of the optic disc flow index has significant correlation to visual field changes
but is not correlated to changes in the thickness of the retinal nerve fiber layer (RNFL).
Additionally, values of the flow index can guide the decision to treat glaucoma suspects or
ocular hypertensive patients [149].
OCTA studies found reduction of microvasculature at the optic disc (Jia et al. [149],
Wang et al. [151], Yip et al. [152], Moghimi et al. [153]) in the peripapillary region (Liu
et al. [148], Yip et al. [152], Yarmohammadi et al. [154], Mammo et al. [155], Akagi et al. [156],
Suwan et al. [157], Scripsema et al. [158], Suh et al. [159]) and in the macula (Yip et al. [152],
Moghimi et al. [153], Yarmohammadi et al. [160], Shoji et al. [161], Takusagawa et al. [162])
in glaucoma patients.
Jia et al. [149] used OCTA to assess optic disc perfusion in 35 subjects (11 glaucomatous,
24 controls). They found a reduction in optic disc flow index from 0.16 ± 0.01 in normal
healthy controls to 0.12 ± 0.02 in glaucomatous patients. Moreover, this reduction in optic
disc perfusion is correlated with visual field defect. This conforms with the findings of
Wang et al. [151], who revealed a reduction in optic disc perfusion correlated with RNFL
thickness, ganglion cell complex thickness, severity of glaucoma stage, and visual field
mean deviation.
Yip et al. [152] noted a reduction of vessel density in the optic nerve head, peripapillary capillaries in 24 glaucomatous eyes versus 29 normal eyes using OCTA. They also
found that the vessel density is reduced at the macular region at the SCP, DCP, outer
retina, and choroid in glaucomatous patients versus controls. Moghimi et al. [153] found
progressive reduction of macular VD and optic nerve head VD in 83 glaucoma patients
using OCTA with a 2-year follow-up period. This progressive reduction of VD is correlated
with thinning of the RNFL and VF loss.
Yarmohammadi et al. [154] studied the relation between density of vessels and visual
field loss in glaucoma using OCTA. They revealed a positive correlation between reduction
of peripapillary density of vessels and progression of visual field loss. However, there
is no significant correlation between reduction of retinal nerve fiber thickness and visual
field loss. They concluded that vascular-functional correlation is more important than
structural-functional correlation. This is consistent with the results of Scripsema et al. [158],
Yarmohammadi et al. [160], and Wang et al. [151]. Mammo et al. [155] investigated peripapillary VD in glaucoma patients using OCTA. They showed a reduction in peripapillary
VD in areas corresponding to RNFL thinning on OCT scans and VF defect on Humphery
perimetry. This vascular-functional correlation is explained by the fact that reduced vascular supply to retinal ganglion cells and their axons is the stage that precedes the death
of ganglion supply. Therefore, OCTA detection of diminished vascular density is an early
indicator of progression of the disease [163].
Akagi et al. [156] investigated peripapillary VD in 60 eyes with glaucoma and hemifield VF defects using OCTA. A reduction was detected in the peripapillary VD that
corresponds to the hemi-field VF defects in glaucomatous eyes that were either non-highly
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myopic or highly myopic. Additionally, they found a reduction in the density of the
optic disc vessel that corresponds to the hemi-field VF defects in non-highly myopic
glaucomatous eyes, but not in highly myopic glaucomatous eyes.
Suh et al. [159] assessed peripapillary VD in 41 glaucomatous eyes with focal lamina
cribrosa (LC) defect versus 41 glaucomatous eyes without LC defect. They revealed that
reduction of peripapillary VD is greater in glaucomatous eyes with LC defect and that
reduction of VD is most marked at the LC defect location.
Suwan et al. [157] compared peripapillary VD among 43 eyes with exfoliation glaucoma (XFG), 33 eyes with exfoliation syndrome (XFS), 31 eyes with primary open angle
glaucoma (POAG), and 45 control healthy eyes. They found that peripapillary VD decreases from the controls to the XFS to the POAG to the XFG progressively.
Yarmohammadi et al. [160] investigated peripapillary VD and macular VD in 58 glaucomatous patients with hemi-field VF defect using OCTA. Authors found a reduction of VD
in the affected hemi-retina when compared with the unaffected hemi-retina. In addition,
the VD of the unaffected hemi-retina of glaucoma eyes is reduced when compared with
VD of healthy control eyes.
Shoji et al. [161] used OCTA to study the average change rate in macular VD in glaucoma patients. They studied eyes of 100 cases (30 glaucoma-suspect, 32 glaucomatous,
38 healthy). The results showed that the average macular VD reduction rate was significantly faster in glaucomatous eyes (−2 : 23%/y) than in glaucoma-suspect (−0 : 87%/y)
than in healthy eyes (−0 : 29%/y).
A study conducted by Takusagawa et al. [162] used projection-resolved OCTA to study
macular perfusion defects in 33 glaucoma patients. They found that the SCP is affected
more than the DCP in glaucomatous eyes. This effect on the SCP in glaucoma is logical, as
the SCP supplies the RNFL, part of the inner plexiform layer (IPL) and ganglion cell layer
(GCL), the anatomic layers that the glaucoma affects the most. Rao et al. [164] investigated
the diagnostic significance of the density of vessels in different regions in OCTA images.
They found that peripapillary VD is more specific than optic nerve VD or macular VD in
diagnosis of glaucoma.
Venugopal et al. [165] conducted an OCTA-based comparison between the intrasession
repeatability of peripapillary and density of macular vessel measurements in 65 eyes (35
glaucomatous, 30 normal). For every eye, authors used three macular scans and three
ONH scans. The results showed that most measurements have similar repeatability for
eyes that are either glaucomatous or normal.
Rao et al. [166] studied choroidal microvascular dropout (CMvD) prevalence in OCTA
of 73 POAG eyes (32 with disc hemorrhage (DH), 41 without DH). Results observed a
dropout in the choroidal microvascular of 17 eyes with DH (53 : 1%) and 13 eyes without
DH (31 : 7%).
Jung et al. [167] conducted a comparative study using 46 eyes with glaucoma and
studied the localization of retinal nerve fiber layer defects in red-free fundus photographs
and OCT en-face images. They found that the localized RNFL defects detected in OCT
en-face structural images of the superficial retinal layer is highly topographically correlated
with the detected defects in red-free photographs.
In summation, OCTA has provided numerous insights into the connection between
the peripapillary vasculature and severity of glaucoma. This suggests possible pathophysiologic mechanisms for glaucoma, a still poorly understood disease, despite its being the
most common optic neuropathy in the world. Despite these gains in knowledge, the clinical
implications for management of glaucoma patients with these findings are as yet unclear,
and visual field changes, pachymetry, RNFL thickness, cup-to-disc ratio, and intraocular
pressure remain the key variables in clinical management.
3.2. Optic Neuropathy
Anterior Ischemic Optic Neuropathy (AION) is known as the acute, severe and painless loss of vision. This visual loss occurs because of ischemia that affects the ONH anterior
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part, which the deep optic nerve plexus supplies [168]. According to different clinical
features and histopathology, AION is partitioned into distinct arteritic (AAION) and nonarteritic (NAION) types [169]. NAION pathophysiology’s most accepted theory is the ONH
insufficiency of the small vessel circulatory [170]. There are major risk factors such as diabetes mellitus, hypertension, optic disc crowded structure and hypercholesterolemia [171].
Balducci et al. [172] presented an OCTA study to analyze AAION and NAAION
features and compare it with ICGA and FA in 4 subjects. One AAION patient and four
NAAION subjects participated in the study. Examination of the subjects was conducted
during two weeks after disease presentation. They found that the ischemic area boundary
could be identified by OCTA at the level of the ONH in the AAION patient and in two
of four NAAION cases, which is confirmed by the boundary of optic disc filling defects
in FA. Additionally, OCTA succeeded in the identification of the ischemic area boundary
at the level of the ONH in the remaining two cases (NAAION), whereas FA failed in that
due to generalized leakage that causes defect in optic disc filling. Several OCTA studies
(Ling et al. [173], Song et al. [174]) revealed reduction of VD of the NAION eyes optic disc
compared to healthy eyes. Mayes et al. [175] revealed impairment of flow in both retinal
and choroidal peripapillary capillaries in OCTA of acute or chronic NAION eyes. This
conforms with Augstburger et al. [176] and Sharma et al. [177] studies.
4. Limitations of OCTA
OCTA is relatively new and has some limitations that might affect its usage in clinical
practice. We review in brief some of these limitations and potential advancement of OCTA
manufacturers to address these limitations.
OCTA’s field of view is much smaller than that of FA. However, this limitation has
been solved in many commercial OCTA devices (wide field OCTA) by using multiple
techniques such as image montaging [18,178,179], OCT-based microangiography [180],
akinetic swept source [104] and extended field imaging technique [122,181], which enabled
up to 12 × 12 mm scanning areas. Commercial OCTA devices often struggle to obtain
high-quality images through small pupils or moderate media opacities through which
FA and OCT are able to transit. Image artifacts are common in clinical practice. OCT
angiography can also mask laser scars since they are “no flow” areas [182]. As mentioned
above, OCTA does not show active leakage either.
In addition, OCTA is unable to detect blood flow below the minimum threshold. This
leads it to miss microaneurysm if blood flow within is below that detected by OCTA [12].
Furthermore, OCTA can mask laser scars since they are eminent “no flow” areas [182].
A limitation of SD-OCTA is its inability to demonstrate choroidal diseases such as
CNV, but this limitation is not present in SS-OCTA, which has longer wavelength with
deeper penetration into the choroid.
On the other hand, different types of artifacts, such as segmentation, blinks, motions,
and projection, may influence interpretation and measurements in OCTA images [183].
Segmentation artifacts occur in many situations, so there could be a need for manual
manipulation of images in these situations to optimize the vascular details to ensure
optimal OCTA interpretation [184]. Blink artifact appears as a black line because the OCT
signal could not reach the retina or the software; accordingly, no movement was detected.
Motion artifact appears as white lines, which represent signal decorrelation over the entire
b-scan. These artifacts usually appear in areas where there is heavy subject movement
when the patient moves or loses fixation. This motion artifact has been corrected in many
OCTA devices by implication of the motion tracking system [185].
Projection artifact happens when the large retinal vessels of the superficial vessel
complex cast shadow on the deep vessel complex of the retina, making identification of the
latter difficult. Moreover, blood vessels in the inner retina give a false shadow of blood
vessels in the outer retina, which is normally avascular. A projection-resolved algorithm
solved this problem to some extent [162]. One of the limitations of OCTA in the assessment
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of the optic nerve vasculature is that it detects overall disc flow measurements without
differentiating retinal circulation from the posterior ciliary artery [186].
5. Conclusions
OCTA is a new imaging technique for diagnosing diseases in retina and optic nerves.
OCTA has advantages over other angiographic imaging techniques, FA and ICG, of being non-invasive, rapid and reliable. OCTA also has the advantage of providing threedimensional images, allowing visualization of retinal and choroidal vasculature in different
layers. OCTA has some disadvantages such as the limited field of view (which has been
partly solved in some commercially available devices), inability to identify leakage, inability to detect blood flow below a certain level, and variable image quality in a real-world,
clinical setting.
OCTA is a helpful imaging modality for diagnosing and monitoring different retinal
and choroidal diseases, including age-related macular degeneration, diabetic retinopathy,
retinal vein occlusion, retinal artery occlusion, ischemic optic neuropathy, and glaucomatous optic neuropathy. Although the technology is still in its infancy, further improvements
in imaging quality, reduction of artifacts, improved transmission through opaque media,
and increased affordability will lead likely to more widespread adoption of the technology. This, in turn, should allow for more rigorous characterizations of these disorders
and others.
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